Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Kyowa Hakko Kirin President Steeped In Antibody Drug Research

This article was originally published in PharmAsia News

Executive Summary

Kyowa Hakko Kirin’s new president is considered an expert researcher of antibodies, reflecting the drug maker’s market focus.

Kyowa Hakko Kirin’s new president is considered an expert researcher of antibodies, reflecting the drug maker’s market focus. Nobuo Hanai, a director and senior executive officer of the firm, was chosen by President Yuzuru Matsuda as his successor as president effective March 22. Matsuda is to continue as a company advisor. Hanai is credited with making Kyowa Hakko Kogyo a leader in antibody therapy. (Click here for more – a subscription may be required)

“Antibody Drug Expert Chosen To Lead Kyowa Hakko Kirin”Nikkei (Japan) (2/1/12)

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC080227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel